amivantamab (Rybrevant)

following a full submission assessed under the orphan equivalent medicine process:

amivantamab (Rybrevant®) is accepted for use within NHSScotland.

Indication under review: in combination with lazertinib for the first line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations.

In a phase III study, the combination of amivantamab and lazertinib significantly prolonged progression-free survival compared with osimertinib monotherapy in adults with treatment-naïve locally advanced or metastatic NSCLC harbouring EGFR Exon 19 deletions or Exon 21 L858R substitution mutations.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.